Received: 3 March 2020
Accepted: 3 June 2020
First Online: 16 June 2020
Ethics approval and consent to participate
: The treatment was approved by IRCCS G.Gaslini Institutional Review Board. Patients legal guardians signed a written informed consent.
: Written informed consent was obtained from the parents for publication.
: MG: Speakers’ fees, consultancies and unrestricted grants from Novartis and Sobi. LOM: speaker’s fees from Novartis and is a recipient of longterm fellowship in autoinflammatory diseases from the European Society of Immunodeficiencies at Giannina Gaslini Institute. The other authors declare that they have no relevant conflicts of interest.